研究单位：[1]Sichuan Baili Pharmaceutical Co., Ltd.[2]Ruijin Hospital[3]SystImmune Inc.[4]Shenzhen Second People's Hospital,Shenzhen,Guangdong,China[5]Affiliated Hospital of Hebei University,Baoding,Hebei,China[6]The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan,China[7]Ruijin Hospital, Shanghai JiaoTong University School of Medicine,Shanghai,Shanghai,China,200025
In this study, the safety and preliminary efficacy of GNC-038 in participants with recurrent or refractory Diffuse Large B-cell lymphoma (DLBCL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-038. The recommended dose for phase II (RP2D) clinical study will also be determined.
